Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Global transcriptomics analysis for TDO2 alteration in human triple-negative breast cancer cell lines

ABSTRACT: Global transcriptomics analysis for TDO2 alteration in human triple-negative breast cancer cell lines

PROVIDER: PRJNA1064872 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27549114_1.fastq.gz	Fastqsanger.gz
	SRR27549114_2.fastq.gz	Fastqsanger.gz
	SRR27549115_1.fastq.gz	Fastqsanger.gz
	SRR27549115_2.fastq.gz	Fastqsanger.gz
	SRR27549116_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 108

Similar Datasets

Global transcriptomics analysis for TDO2 alteration in human triple-negative breast cancer cell lines

Project description:To elucidate the downstream transcriptomics changes in reponse to TDO2 alteration including shRNA knockdown, overexpression and TDO2/IDO duak inhibitor treatments in human triple-negative breast cancer cell lines.

2025-01-02 | GSE253237 | GEO

Spatial transcriptomics of triple negative breast cancer

Project description:Spatial transcriptomics of triple negative breast cancer

| PRJNA866496 | ENA

Triple therapy reduced metastasis in triple-negative breast cancer.

Project description:Triple therapy reduced metastasis in triple-negative breast cancer.

| PRJNA832953 | ENA

Triple therapy reduced metastasis in triple-negative breast cancer

Project description:Triple therapy reduced metastasis in triple-negative breast cancer

| PRJNA857888 | ENA

Spatial transcriptomics of triple negative breast cancer

Project description:Triple negative breast cancer (TNBC) is an aggressive and clinically challenging subtype of breast cancer. TNBC disporportionately affects African-American (AA) women, but the biological basis of this disparity is not understood. To gain a better understanding of TNBC, particularly in AA patients, we applied spatial transcriptomics to thoroughly characterize gene expression and tissue architecture in TNBC. Our cohort consisted of 22 patients, 15 of whom were AA, and 7 who were Caucasian. We obtained 2 sections from each patient's tumor (except for patient 19) for a total of 43 samples.

2022-11-02 | GSE210616 | GEO

TDO2 promotes hepatocellular carcinoma by regulating tryptophan-kynurenine pathway

Project description:Objective: This study aims to investigate the impact of differentially expressed tryptophan 2,3-dioxygenase (TDO2) on hepatocellular carcinoma (HCC) growth and its role in regulating ADCY5 and PRKAR2B expression in cells and tissues. Methods: Serum amino acid profiles in patients with HCC were analyzed via metabolomics. Lentiviral transfection was used to knock down and overexpress TDO2 in cells, with corresponding subcutaneous tumor models established in nude mice. A rat model of primary hepatocellular carcinoma was generated through intraperitoneal injection of N-nitrosodiethylamine (DEN). Cellular responses were assessed using CCK8, Annexin V-PE/7ADD double staining, and scratch assays. Transcriptome sequencing was performed to analyze genetic alterations in subcutaneous tumor tissues, while RT-qPCR and Western blotting were employed to quantify mRNA and protein levels. Results: TDO2 knockdown inhibited hepatocellular carcinoma cell proliferation and migration, while promoting apoptosis. Conversely, TDO2 overexpression enhanced cell proliferation and migration. Moreover, ADCY5 overexpression reverses the tumor-suppressive effects elicited by TDO2 knockdown. Transcriptome sequencing revealed an association between TDO2 and the downstream genes ADCY5 and PRKAR2B. In both cellular and animal models, mRNA levels of ADCY5 and PRKAR2B were positively correlated with TDO2 expression. Conclusion: TDO2 may facilitate HCC growth and metastasis by activating ADCY5 expression and its downstream target PRKAR2B.

2025-10-10 | GSE309614 | GEO

Global phosphotyrosine survey reveals activation of multiple tyrosine kinase signaling pathways in triple negative breast cancer

Project description:About 15-20% of all breast cancers are triple negative breast cancers, which are often highly aggressive. We performed global quantitative phosphotyrosine profiling of a large panel of triple negative breast cancer cell lines using high resolution Fourier transform mass spectrometry. Our study identified 1,903 tyrosine-phosphorylated peptides derived from 969 proteins. Heterogeneous activation of tyrosine kinases was observed in triple negative breast cancer derived cell lines.

2016-07-06 | PXD001222 | Pride

Triple Negative Breast tumors: SPARC Positive Tumors vs SPARC Negative Tumors

Project description:The aim of this study was evaluate the transcriptome changes in the comparison between triple negative tumors with increased SPARC expression and triple negative tumors with decreased SPARC expression according to Nagai et al., 2011 (Breast Cancer Res Treat (2011) 126:1–14) The results generated could be of particular interest to better define the prognostic impact of SPARC expression in triple negative breast tumors

2018-07-01 | GSE98931 | GEO

Metastasis in triple-negative breast cancer

Project description:Metastasis in triple-negative breast cancer

| PRJNA437929 | ENA

FOXC1 in triple negative breast cancer

Project description:FOXC1 in triple negative breast cancer

| PRJNA882754 | ENA